DS
ABUS icon

David Shaw’s Arbutus Biopharma ABUS Stock Holding History

David Shaw’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-30,000
Closed -$455K – 3584
2014
Q4 		$455K Hold
30,000
– – ﹤0.01% 3399
2014
Q3 		$634K Buy
+30,000
New +$490K ﹤0.01% 3157

Other funds holding ABUS

California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's ABUS Position: Q2 2026 in Review

David Shaw increased its Arbutus Biopharma (ABUS) stake by 167% in Q2 2026, buying an estimated $1.05M and bringing the position to 381,863 shares worth $1.83M. The position accounts for ﹤0.01% of the portfolio, ranked #3272.

David Shaw first reported a position in ABUS in Q3 2014 and has held it in 27 quarters since. The position peaked at $29.4M in Q1 2015. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • David Shaw held 381,863 shares of Arbutus Biopharma worth $1.83M as of Q2 2026.
  • David Shaw bought 238,662 Arbutus Biopharma shares in Q2 2026, an estimated $1.05M.
  • Arbutus Biopharma made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3272 holding.
  • David Shaw first reported a position in Arbutus Biopharma in Q3 2014 and has held it in 27 quarters since.
  • David Shaw's Arbutus Biopharma position peaked at $29.4M in Q1 2015.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.